http://www.velonews.com/news/fea/10587.0.html
Anti-doping tests conducted during the recently completed 93rd Tour de France have turned up an "adverse analytical finding," the UCI confirmed Wednesday.
The name of the rider will not be released to the public until further tests are conducted. The rider and their team, national doping and cycling federations as well as the World-Anti Doping Agency have been notified.
Under anti-doping rules, a second "B" sample will be tested to confirm the results. If both samples come up positive, the rider will face sanctions for a failed doping test. If the "B" sample comes back negative, no sanction will be imposed.
The UCI said it received a report Wednesday from the anti-doping laboratory in Paris noting the "A" sample positive taken during the 2006 Tour, but did not divulge more details.
"The adverse analytical finding received this morning relates to the first analysis, and will have to be confirmed either by a counter-analysis required by the rider, or by the fact that the rider renounces to that counter analysis," the UCI said in a statement.
"The World Anti-doping Code and the Anti-doping Rules of the UCI do not allow to make the name of the concerned rider public, as well as other information that may allow identification ..." the statement added.
The test was carried out by France's national anti-doping laboratory at Chatenay-Malabry.
UCI president Pat McQuaid told AFP he would be dismayed if the test was confirmed but vowed no let-up in the war on drug cheats.
"From my point of view it's intolerable and we're determined to root out this problem and deal with it," Mcquaid said in a telephone interview. "At the moment I'm concerned over the A sample result. If the B sample turns out to be positive, I'll be angry."
This year's Tour was rocked by a drugs scandal on the eve of the race which saw 13 riders, including pre-race favourites Jan Ullrich and Ivan Basso, barred from taking part after they were implicated in a Spanish blood-doping ring.
It was the latest in a series of high-profile drugs controversies to tarnish cycling over the past decade, with the Tour de France being particularly hard hit.
Anti-doping tests conducted during the recently completed 93rd Tour de France have turned up an "adverse analytical finding," the UCI confirmed Wednesday.
The name of the rider will not be released to the public until further tests are conducted. The rider and their team, national doping and cycling federations as well as the World-Anti Doping Agency have been notified.
Under anti-doping rules, a second "B" sample will be tested to confirm the results. If both samples come up positive, the rider will face sanctions for a failed doping test. If the "B" sample comes back negative, no sanction will be imposed.
The UCI said it received a report Wednesday from the anti-doping laboratory in Paris noting the "A" sample positive taken during the 2006 Tour, but did not divulge more details.
"The adverse analytical finding received this morning relates to the first analysis, and will have to be confirmed either by a counter-analysis required by the rider, or by the fact that the rider renounces to that counter analysis," the UCI said in a statement.
"The World Anti-doping Code and the Anti-doping Rules of the UCI do not allow to make the name of the concerned rider public, as well as other information that may allow identification ..." the statement added.
The test was carried out by France's national anti-doping laboratory at Chatenay-Malabry.
UCI president Pat McQuaid told AFP he would be dismayed if the test was confirmed but vowed no let-up in the war on drug cheats.
"From my point of view it's intolerable and we're determined to root out this problem and deal with it," Mcquaid said in a telephone interview. "At the moment I'm concerned over the A sample result. If the B sample turns out to be positive, I'll be angry."
This year's Tour was rocked by a drugs scandal on the eve of the race which saw 13 riders, including pre-race favourites Jan Ullrich and Ivan Basso, barred from taking part after they were implicated in a Spanish blood-doping ring.
It was the latest in a series of high-profile drugs controversies to tarnish cycling over the past decade, with the Tour de France being particularly hard hit.
